RESOLVENCT05608681
A Trial to Evaluate EP-104GI in Adults With Eosinophilic Esophagitis (EoE).
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 12 versions: 12 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 24 words
- Trial sites expanded: 23 → 33 locations
- Secondary endpoints: details revised at 16 of 19 entries
- Minor Study sites: 19 to 23v11
- Notable Primary endpoints revised (6)
- Study sites: 7 to 19
- Secondary endpoints revised (19)
Notable Enrollment target: 57 to 117v9 Show 8 more changesShow less
- Primary and study completion dates: Dec 2025 to Dec 2026
- Eligibility criteria expanded, about 65 words
- Primary endpoints revised (6)
- Study sites: 5 to 7
- Interventions: EP-104IAR (Drug) to EP-104GI (Drug), Matching vehicle control (Other)
- Secondary endpoints: 28 to 19
- Study title revised
- Study arms: 9 to 12
Notable Enrollment target: 24 to 57v8 Show 5 more changesShow less
- Primary and study completion dates: Nov 2024 to Dec 2025
- Primary endpoints: 4 to 6
- Secondary endpoints: 16 to 28
- Site details revised at 2 of 5 sites
- Study arms: 8 to 9
Show 6 earlier versionsHide 6 earlier versions
- Notable Phase: Phase 1 to Phase 1/2
- Study title expanded, about 2 words
- Minor Study sites: 4 to 5v6
- Notable Primary and study completion dates: Sep 2023 to Nov 2024v5
- Minor Site details revised at 1 of 4 sitesv4
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 4
- Start date changed from estimate of Jan 2023 to Mar 31, 2023
- Notable Start date: Nov 2022 to Jan 2023v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (19)
Show 14 moreShow less
Arms and interventions
4 submucosal injections of EP-104GI administered during an EGD procedure at the Baseline/Dosing visit.
8 submucosal injections of EP-104GI administered during an EGD procedure at the Baseline/Dosing visit.
8 submucosal injections of EP-104GI administered during an EGD procedure at the Baseline/Dosing visit.
12 submucosal injections of EP-104GI administered during an EGD procedure at the Baseline/Dosing visit.
12 submucosal injections of EP-104GI administered during an EGD procedure at the Baseline/Dosing visit.
16 submucosal injections of EP-104GI administered during an EGD procedure at the Baseline/Dosing visit.
20 submucosal injections of EP-104GI administered during an EGD procedure at the Baseline/Dosing visit.
16 submucosal injections of EP-104GI administered during an EGD procedure at the Baseline/Dosing visit.
20 submucosal injections of EP-104GI administered during an EGD procedure at the Baseline/Dosing visit.
20 submucosal injections of EP-104GI administered during an EGD procedure at the Baseline/Dosing visit.
20 submucosal injections of EP-104GI administered during an EGD procedure at the Baseline/Dosing visit.
20 submucosal injections of EP-104GI administered during an EGD procedure at the Baseline/Dosing visit.
Drugs: EP-104GI
Other: Matching vehicle control
Sites
33 sites in 6 countries
Australia 12, Canada 9, United Kingdom 6, New Zealand 3, Netherlands 2, Switzerland 1